TNS Healthcare launches DetailMed

Share this article:
TNS Healthcare has unveiled a call assessment tool measuring detail effectiveness across countries, brands and categories. According to a company statement, DetailMed is tracked continuously online, and allows users to monitor the quality of their own sales calls, as well as competitors' detailing. 
“DetailMed is the first continuous call assessment tool built to support global brands. With DetailMed, pharmaceutical companies finally have a solution that lets them measure message impact and call quality across countries—a strategic necessity for fully understanding and optimizing brand performance,” said David Owen, director at TNS Healthcare, in a statement.

Info gathered by DetailMed is presented through an online dashboard, a type of user interface increasingly used for tracking ROI. Users can customize the service by choosing the geographic level, frequency of results or specific physicians. 
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Is your marketing strategy stuck in 2005?

Is your marketing strategy stuck in 2005?

It is not enough to just have a killer black book or Rolodex. The market needs agile, swift marketing

Is guidance stifling social media?

Recent FDA draft guidance was meant to help companies create FDA-compliant tweets and handle third-party misinformation on the web. What other obstacles lie in the path of effective social media use?

FDA social media guides draw flak

FDA social media guides draw flak

Two FDA guidance documents on how health product manufacturers may participate in social media have drawn criticism from industry and consumer groups.